Skip to main content

REMODELADO Y DISFUNCION CARDIACA EN PACIENTES CON PREECLAMPSIA REGULADO POR EL AMBIENTE ANTI-ANGIOGENICO: ESTUDIO CLINICO Y EXPERIMENTAL.

PI19/00702

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Execution centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cardiovascular risk assessment in women at high risk for pre-eclampsia in first half of pregnancy

  • Ullmo, Johana|||0000-0002-9313-917X
  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Bos-Real, L.|||0000-0002-6159-0644
  • Padilla-Lopez, Mireia|||0000-0002-4374-3870
  • Coma-Barbarà, Marina
  • Martorell, Silvia
  • Mora Brugués, Josefina|||0000-0001-6777-5132
  • Ordóñez, J. (Jordi)|||0000-0003-4896-5832
  • Llurba, Elisa|||0000-0003-4048-6407
Background: Women diagnosed with pre-eclampsia (PE), especially those with early-onset and severe forms, are at heightened risk of future cardiovascular disease (CVD). It is uncertain if women at high-risk for PE present cardiovascular impairment at the beginning of pregnancy. The aim of this study was to assess cardiovascular biomarkers and cardiac function in the first half of pregnancy in women at high-risk for PE. Methods: This was a prospective cohort study including women attending first trimester screening for PE. Risk of PE in the first trimester was calculated using a previously validated model, which includes maternal factors and biophysical markers. A cut-off of 1 in 250 was used to classify high-risk for developing PE. Maternal echocardiographic function and morphometry were evaluated, and peripheral blood samples were obtained to assess hematological and biochemical variables, including lipid profile and cardiovascular and angiogenic factors. Results: A total of 349 pregnant individuals were included; 257 at high-risk and 92 at low-risk for PE. Maternal echocardiography was performed at a mean ± SD gestational age of 14.9 ± 1.3 weeks and blood sampling at 16.3 ± 1.9 weeks. The high-risk PE group exhibited a significantly worse lipid profile (lower levels of high-density lipoproteins 69.7 ± 14.2 vs 74.0 ± 14.6 mg/dL, p=0.020), lower placental growth factor (0.89 ± 0.63 vs 1.15 ± 0.58 MoM, p<0.001), and significantly lower levels of N-terminal pro-brain natriuretic peptide (51.0 ± 2.1 vs 52.1 ± 2.0 ng/L, p=0.008). Echocardiographic evaluation indicated concentric remodeling, along with an altered diastolic pattern in the high-risk group. Conclusions: Women at high risk of developing PE exhibit differences in lipid profile, angiogenic factors, and echocardiographic parameters, indicative of cardiac maladaptation or impairment during the first half of pregnancy. These findings suggest a link between subclinical cardiovascular dysfunction, PE development and later CVD risk.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

N-terminal pro B-type natriuretic peptide as biomarker to predict pre-eclampsia and maternal-fetal complications

  • Nan, Madalina Nicoleta|||0009-0001-2794-447X
  • Universitat Autònoma de Barcelona.
  • Garrido-Giménez, Carmen|||0000-0003-2180-1715
  • Mora Brugués, Josefina|||0000-0001-6777-5132
  • Platero, Judit|||0000-0001-6007-9855
  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Llurba, Elisa|||0000-0003-4048-6407
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • García Manau, Pablo|||0000-0002-2415-1626
  • Ullmo, Johana|||0000-0002-9313-917X
  • Sánchez García, Olga|||0000-0002-5279-440X
  • Vila-Cortés, M.
  • Pelegay, M. J.
  • Ricart, M
  • Muñoz-Abellana, B.
  • Barrios, X. Gabaldó
Objective: A soluble fms-like tyrosine kinase-1 (sFlt-1)-to-placental growth factor (PlGF) ratio cut-off of 38 is currently considered optimal for ruling out pre-eclampsia (PE); however, implementation of this ratio in clinical practice is limited. N-terminal pro B-type natriuretic peptide (NT-proBNP) is elevated in PE owing to the cardiovascular effects of this disease. This study aimed to identify the predictive performance of NT-proBNP to detect PE and placental complications within 1 week after assessment, and compare it with the predictive performance of the sFlt-1/PlGF ratio. High-sensitivity troponin T (hs-TnT) and uric acid were also evaluated. Methods: This was a prospective nested case-control study conducted in five Spanish centers between March 2018 and December 2020, and comprised women with a singleton pregnancy and suspected PE between 24 + 0 and 41 + 0 weeks' gestation. We evaluated the ability of the sFlt-1/PlGF ratio, NT-proBNP, hs-TnT and uric acid to predict the development of any-onset (at any gestational age), early-onset (before 34 weeks) or term (at or after 37 weeks) PE within 1 week or 4 weeks after assessment. Predictive performance was assessed by estimating negative predictive values, positive predictive values, sensitivity, specificity and areas under the receiver-operating-characteristics curves (AUCs) for these biomarkers, with corresponding 95% CIs. We performed post-hoc exploratory analyses of associations between the sFlt-1/PlGF ratio, NT-proBNP, hs-TnT and uric acid in women who developed PE, as well as in women who developed complicated PE (PE plus fetal growth restriction, stillbirth or placental abruption) within 1 week and 4 weeks after assessment. Results: A total of 323 women with suspected PE at or before 41 + 0 weeks were enrolled in the study, of whom seven were lost to follow-up. The final analysis included 316 eligible participants, with 424 samples. The overall incidence of PE was 23.4% (n = 74) and early-onset PE developed in 8.5% (n = 27) of cases. The sFlt-1/PlGF ratio and NT-proBNP exhibited similar abilities to predict early-onset PE within 1 week after assessment (AUC, 0.970 (95% CI, 0.932-1.000) and 0.971 (95% CI, 0.942-1.000), respectively). hs-TnT and uric acid demonstrated inferior predictive capability compared with the sFlt-1/PlGF ratio for the prediction of any-onset PE, early-onset PE and term PE within 1 week and 4 weeks after assessment. The optimal cut-off for NT-proBNP was 116 pg/mL. At this cut-off, NT-proBNP showed a sensitivity of 90.9% (95% CI, 70.8-98.9%) and a specificity of 94.3% (95% CI, 91.2-96.5%), with a positive predictive value of 5.7% (95% CI, 3.7-8.7%) and a negative predictive value of 99.9% (95% CI, 99.9-100%) in predicting early-onset PE within 1 week of assessment, which was comparable with that of the sFlt-1/PlGF ratio. Participants with PE-related complications had higher levels of all biomarkers, but only NT-proBNP showed a similar predictive ability to the sFlt-1/PlGF ratio for complicated PE within 1 week after assessment (AUC, 0.818 (95% CI, 0.706-0.930) vs 0.822 (95% CI, 0.723-0.921), respectively). Conclusion: An NT-proBNP cut-off value of 116 pg/mL has a similar diagnostic performance to that of the sFlt-1/PlGF ratio in predicting the diagnosis of early-onset PE within 1 week after assessment. Thus, NT-proBNP could be used in clinical practice for the early identification and management of PE, particularly in cases for which the sFlt-1/PlGF ratio is not available. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cardiac dysfunction and remodeling regulated by anti-angiogenic environment in patients with preeclampsia, the ANGIOCOR prospective cohort study protocol

  • Ullmo, Johana|||0000-0002-9313-917X
  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Sánchez García, Olga|||0000-0002-5279-440X
  • Bos-Real, L.|||0000-0002-6159-0644
  • Fernandez-Llama, Patricia|||0000-0002-7472-2124
  • Calero, Francesca|||0000-0002-5758-0769
  • Domínguez Gallardo, Carla|||0000-0002-5365-1005
  • Garrido-Giménez, Carmen|||0000-0003-2180-1715
  • Trilla, Cristina|||0000-0002-5650-1790
  • Carreras Costa, Francesc|||0000-0002-1944-0562
  • Sionis, Alessandro|||0000-0003-0843-9512
  • Mora, J.
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • Ordóñez, J. (Jordi)|||0000-0003-4896-5832
  • Llurba, Elisa|||0000-0003-4048-6407
Background: Cardiovascular diseases (CVD) are cause of increased morbidity and mortality in spite of advances for diagnosis and treatment. Changes during pregnancy affect importantly the maternal CV system. Pregnant women that develop preeclampsia (PE) have higher risk (up to 4 times) of clinical CVD in the short- and long-term. Predominance of an anti-angiogenic environment during pregnancy is known as main cause of PE, but its relationship with CV complications is still under research. We hypothesize that angiogenic factors are associated to maternal cardiac dysfunction/remodeling and that these may be detected by new cardiac biomarkers and maternal echocardiography. Methods: Prospective cohort study of pregnant women with high-risk of PE in first trimester screening, established diagnosis of PE during gestation, and healthy pregnant women (total intended sample size n = 440). Placental biochemical and biophysical cardiovascular markers will be assessed in the first and third trimesters of pregnancy, along with maternal echocardiographic parameters. Fetal cardiac function at third trimester of pregnancy will be also evaluated and correlated with maternal variables. Maternal cardiac function assessment will be determined 12 months after delivery, and correlation with CV and PE risk variables obtained during pregnancy will be evaluated. Discussion: The study will contribute to characterize the relationship between anti-angiogenic environment and maternal CV dysfunction/remodeling, during and after pregnancy, as well as its impact on future CVD risk in patients with PE. The ultimate goal is to improve CV health of women with high-risk or previous PE, and thus, reduce the burden of the disease. Trial registration: NCT04162236.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Predictive Model for Preeclampsia Combining sFlt-1, PlGF, NT-proBNP, and Uric Acid as Biomarkers

  • Garrido-Giménez, Carmen|||0000-0003-2180-1715
  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Álvarez Menéndez, Francisco V.|||0000-0002-2553-5402
  • Nan, Madalina Nicoleta|||0009-0001-2794-447X
  • Carretero, Francisco
  • Fernández-Oliva, Antonio|||0000-0002-8610-2600
  • Mora Brugués, Josefina|||0000-0001-6777-5132
  • Sánchez García, Olga|||0000-0002-5279-440X
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • Alijotas-Reig, Jaume|||0000-0002-9212-3619
  • Llurba, Elisa|||0000-0003-4048-6407
N-terminal pro-brain natriuretic peptide (NT-proBNP) and uric acid are elevated in pregnancies with preeclampsia (PE). Short-term prediction of PE using angiogenic factors has many false-positive results. Our objective was to validate a machine-learning model (MLM) to predict PE in patients with clinical suspicion, and evaluate if the model performed better than the sFlt-1/PlGF ratio alone. A multicentric cohort study of pregnancies with suspected PE between 24 +0 and 36 +6 weeks was used. The MLM included six predictors: gestational age, chronic hypertension, sFlt-1, PlGF, NT-proBNP, and uric acid. A total of 936 serum samples from 597 women were included. The PPV of the MLM for PE following 6 weeks was 83.1% (95% CI 78.5-88.2) compared to 72.8% (95% CI 67.4-78.4) for the sFlt-1/PlGF ratio. The specificity of the model was better; 94.9% vs. 91%, respectively. The AUC was significantly improved compared to the ratio alone [0.941 (95% CI 0.926-0.956) vs. 0.901 (95% CI 0.880-0.921), p < 0.05]. For prediction of preterm PE within 1 week, the AUC of the MLM was 0.954 (95% CI 0.937-0.968); significantly greater than the ratio alone [0.914 (95% CI 0.890-0.934), p < 0.01]. To conclude, an MLM combining the sFlt-1/PlGF ratio, NT-proBNP, and uric acid performs better to predict preterm PE compared to the sFlt-1/PlGF ratio alone, potentially increasing clinical precision.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Fetal Left Ventricle Function Evaluated by Two-Dimensional Speckle-Tracking Echocardiography across Clinical Stages of Severity in Growth-Restricted Fetuses

  • Domínguez Gallardo, Carla|||0000-0002-5365-1005
  • Ginjaume García, Nuria|||0000-0003-0785-0115
  • Ullmo, Johana|||0000-0002-9313-917X
  • Parra Roca, Juan|||0000-0001-6011-7815
  • Vázquez Fariñas, Ana|||0000-0001-6732-1667
  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Llurba, Elisa|||0000-0003-4048-6407
Fetal growth restriction (FGR) can result in adverse perinatal outcomes due to cardiac dysfunction. This study used 2D speckle-tracking echocardiography to assess left ventricle (LV) longitudinal strain across FGR severity stages. A prospective longitudinal cohort study measured global (GLS) and segmental LV longitudinal strain in FGR fetuses, with evaluations conducted at various time points. FGR was classified into subtypes based on published criteria using fetal weight centile and Doppler parameters. A linear mixed model was employed to analyze repeated measures and compare Z-score measurements between groups throughout gestational age. The study included 40 FGR fetuses and a total of 107 evaluations were performed: 21 from small for gestational age (SGA), 74 from the FGR stage I, and 12 from the FGR stage ≥ II. The results indicate that SGA and stage I FGR fetuses exhibit higher LV GLS than stages ≥ II. Throughout gestation, SGA and FGR stage I fetuses showed similar behavior with consistently better LV GLS values when compared to FGR stages ≥ II. No significant differences were observed in LV GLS strain behavior between SGA and FGR stage I. In conclusion, all FGRs show signs of early cardiac dysfunction, with severe cases demonstrating significantly a lower LV GLS when compared to mild cases, suggesting deterioration of cardiac dysfunction with progression of fetal compromise.